
N George Mikhaeel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7352518/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 2014, 32, 3048-3058.	1.6	1,269
2	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2014, 89, 854-862.	0.8	479
3	Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1209-1219.	6.4	217
4	Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1142-1154.	6.4	106
5	Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 22-26.	6.4	91
6	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood, 2018, 132, 1635-1646.	1.4	86
7	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	1.4	85
8	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
9	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
10	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	2.8	65
11	Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. Journal of Nuclear Medicine, 2021, 62, 332-337.	5.0	53
12	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology, 2022, 40, 2352-2360.	1.6	53
13	When should <scp>FDG</scp> â€ <scp>PET</scp> be used in the modern management of lymphoma?. British Journal of Haematology, 2014, 164, 315-328.	2.5	52
14	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.8	46
15	The role of FDG PET in the management of lymphoma: what is the evidence base?. Nuclear Medicine Communications, 2007, 28, 335-354.	1.1	43
16	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Advances, 2021, 5, 2375-2384.	5.2	40
17	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large Bâ€cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	2.5	34
18	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1167-1169.	5.0	32

N GEORGE MIKHAEEL

#	Article	IF	CITATIONS
19	Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. Leukemia and Lymphoma, 2009, 50, 1931-1936.	1.3	30
20	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2019, 104, 501-512.	0.8	30
21	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
22	FDGâ€PET/CT after two cycles of R HOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology, 2021, 192, 504-513.	2.5	27
23	Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiotherapy and Oncology, 2018, 129, 449-455.	0.6	25
24	PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Current Hematologic Malignancy Reports, 2016, 11, 185-195.	2.3	22
25	Total tumor burden in lymphoma – an evolving strong prognostic parameter. British Journal of Radiology, 2021, 94, 20210448.	2.2	18
26	Are We Ready for Positron Emission Tomography/Computed Tomography-based Target Volume Definition in Lymphoma Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 14-20.	0.8	14
27	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1–3a follicular lymphoma. British Journal of Haematology, 2018, 182, 297-301.	2.5	7
28	PET response–guided radiotherapy for advanced DLBCL?. Blood, 2021, 137, 866-867.	1.4	7
29	Is 70 the new 60? New international prognostic index with an older age cut-off for diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2487-2488.	1.3	5
30	Harnessing benefit of highly conformal RT techniques for lymphoma patients. British Journal of Radiology, 2021, 94, 20210469.	2.2	4
31	Pleural plasmacytomas – the role of radiotherapy. British Journal of Haematology, 2020, 190, e160-e162.	2.5	3
32	Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 1655.2-1656.	5.0	3
33	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leukemia and Lymphoma, 2018, 59, 2650-2659.	1.3	2
34	Hotter is not more aggressive: baseline SUVmax in FL. Blood, 2020, 135, 1191-1192.	1.4	2
35	A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. British Journal of Radiology, 2021, 94, 20210285.	2.2	1
36	Pilot Evaluation of the Value of FDG PET-CT after One and Two Cycles of Salvage Chemotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's and Hodgkin's Lymphoma. Blood, 2008, 112, 4951-4951.	1.4	0